TEVA Q3 2021 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$36B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$3.9B-2.3% YoY

Gross Profit

$1.8B46.2% margin

Operating Income

$623M16.0% margin

Net Income

$292M7.5% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

-0.6%

Cash Flow

Operating Cash Flow

$529M

Free Cash Flow

$383M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$47.9B

Total Liabilities

$36.4B

Stockholders' Equity

$10.5B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.9B	$4.0B	-2.3%
Gross Profit	$1.8B	$1.9B	-3.1%
Operating Income	$623M	-$4.3B	+114.3%
Net Income	$292M	-$4.3B	+106.7%

Revenue Segments

Product

$3.3B86%

Distribution Service

$378M10%

Product and Service, Other

$130M3%

License

$38M1%

Geographic Segments

North America Segment

$1.9B51%

Europe Segment

$1.2B33%

International Markets

$569M16%